Navigation Links
Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
Date:4/4/2011

PITTSBURGH, April 4, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan® Ophthalmic Solution, an eyedrop that lowers pressure in the eye.  

Mylan President Heather Bresch said: "We are very pleased to introduce this product to the market as it represents Mylan's first ophthalmic solution. This signifies a new internal development capability for the company, and we currently have in development a number of additional products in this important category."  

Latanoprost Ophthalmic Solution had U.S. sales of approximately $711 million for the 12 months ending Dec. 31, 2010, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 168 ANDAs pending FDA approval representing $98.7 billion in annual sales, according to IMS Health. Forty-eight of these pending ANDAs are potential first-to-file opportunities, representing $25.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
2. Moodys Upgrades Mylan
3. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®
4. Mylan Receives Approval for Generic Version of Neurontin® Capsules
5. Mylan Launches First Generic Version of Vfend® Tablets
6. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
7. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
8. Mylan Announces Lipitor® Settlement Agreement
9. Mylan Announces Caduet® Settlement Agreement
10. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... -- On 28 May, 194 Member States made ... the 69 th World Health Assembly, governments unanimously voted ... the greatest global commitment in viral hepatitis to date. ... and C by 2030 and includes a set of prevention ... by 65% and increase treatment to 80%, saving 7.1 million ...
(Date:5/30/2016)... 2016 LifeScienceIndustryResearch.com adds "Ulcerative ... report with comprehensive information on the therapeutic development ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Ulcerative ...
(Date:5/27/2016)... -- A new study highlights the necessity of health literacy within the technology advancement of ... of Radiology , a majority of oncology patients undergo imaging screenings without understanding the ... ... ... Medical Diagnostic Imaging Ampronix ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in ... Networks Co., the leading provider of secure mobile remote access solution for Japan ... leading CACHATTO remote access solution. Splashtop for CACHATTO will be available as ...
(Date:5/31/2016)... ... May 31, 2016 , ... The ... advanced Artificial Intelligence (AI) and the latest in Clinical Patient Pod ... integrating predictive analytic outputs directly into the clinical workflow. These insights are empowering ...
(Date:5/31/2016)... Maryland (PRWEB) , ... May 31, 2016 , ... ... to attribute calls back to particular advertising campaigns, to monitor the performance of ... that they can maximize conversions and revenue. The software allows customers to record, ...
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... San Francisco, CA (PRWEB) , ... May 31, 2016 , ... ... and cases for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit ... lightweight, durable waxed canvas or ballistic nylon, the Duo is smartly designed ...
Breaking Medicine News(10 mins):